| Title： | Expert consensus on multiple drug use for respiratory system diseases guided by genetic testing |
| Edition： | Original |
| Classification： | Experts consensus |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | Doctors, pharmacists, nurses, laboratory technicians |
| Evidence classification method： | OCEBM |
| Development unit： | Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine |
| Registration time: | 2023-10-30 |
| Registration number： | PREPARE-2023CN820 |
| Purpose of the guideline: | Multiple medication is very common in patients with chronic respiratory diseases, and some drugs are affected by the drug metabolism enzymes or transporters, thereby affecting the efficacy or producing adverse reactions. Reasonably adjusting medication through gene testing is also a necessary means. The Clinical Pharmacy Branch of the Chinese Medical Association has organized relevant experts to use foreign drug risk assessment tools and relevant evidence-based results to develop the "Expert Consensus on Gene Testing Guidance for Multiple Drug Use in Respiratory System Diseases" for patients with chronic respiratory diseases who use multiple drugs. The consensus will be further promoted and applied to the clinical treatment practice of respiratory diseases, providing information for individual institutions to develop clinical plans and reduce the adverse clinical outcomes of multiple drug use in China. |
